Pharma Five is a registered firm based in India. We specialize in Named Patient Imports, Imported cancer drugs, Imported medicines in india.
Contact Us Pharma Five Door No. 74, Old No. 26, Fagun Mansion, 3rd Floor, Ethiraj Salai, Egmore, Chennai - 600008 +916374297988 info@pharmafive.org
Medicine name : Anktiva
Generic name : Nogapendekin alfa inbakicept-pmln
Manufactured By : Altor BioScience, LLC (ImmunityBio)
Indications : Treatment of adults with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), including carcinoma in situ with or without papillary tumors and high-grade papillary-only tumors.
Medicine Description : An immunotherapy used with Bacillus Calmette-Guérin (BCG) for adults with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). Anktiva (Nogapendekin alfa inbakicept-pmln) stimulates immune cell activity to help the body recognise and attack bladder cancer cells.
Anktiva (Nogapendekin Alfa Inbakicept-pmln) is an immunotherapy medicine used with Bacillus Calmette-Guérin (BCG) to treat adults with BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC).
Anktiva activates the interleukin-15 (IL-15) receptor pathway, stimulating immune cells such as natural killer cells and T cells to help the body fight bladder cancer.
Anktiva is prescribed for adults with BCG-unresponsive non-muscle-invasive bladder cancer. A specialist evaluates the cancer type, previous BCG treatment and overall health before recommending it.
Anktiva is administered directly into the bladder through a urinary catheter by a qualified healthcare professional, in combination with BCG. The prescribed treatment schedule and bladder-retention instructions must be followed.
Common side effects include increased creatinine, painful urination, blood in the urine, frequent urination, urinary urgency, urinary tract infection, increased potassium, muscle or joint pain, chills and fever.
Yes. Anktiva treatment requires monitoring for urinary complications and other adverse reactions. Delaying recommended bladder removal surgery when cancer persists may increase the risk of cancer spreading. Report prolonged urinary symptoms or blood in the urine to your doctor.
The treatment duration depends on the prescribed induction and maintenance schedule, treatment response and medical evaluation. Your specialist will determine whether additional treatment is appropriate.
Consult your doctor before consuming alcohol during treatment. Discuss alcohol use in relation to your overall health, other medicines and any treatment-related symptoms.
Anktiva may cause fetal harm if systemic exposure occurs. Pregnancy status should be checked before treatment, and females of reproductive potential should use effective contraception during treatment and for one week after the last dose.
Tell your doctor about all prescription medicines, over-the-counter products, vitamins and supplements you use. Your healthcare team can assess potential interactions and treatment-related risks.
If you miss a scheduled Anktiva treatment appointment, contact your doctor or treatment centre as soon as possible to arrange further instructions. Do not attempt to administer the medicine yourself.
Anktiva is administered directly into the bladder, not taken by mouth. It does not require oral food-related dosing instructions; follow your doctor's advice about your usual diet.
Attend all scheduled bladder examinations and follow-up appointments. Maintain adequate hydration after treatment, report prolonged urinary symptoms or red-coloured urine, and discuss any planned surgery with your specialist.
Store Anktiva vials in a refrigerator at 2°C to 8°C (36°F to 46°F), in the original carton to protect them from light. Do not freeze or shake the vials.
Pharma Five can provide guidance and assistance with accessing Anktiva through applicable medicine import procedures for personal medical use. Import is subject to regulatory requirements and the necessary medical documentation. Pharma Five assists in its procurement.